$ASNS
ACTELIS NETWORKS INC

2024 Q4 Form 10-Q Financial Statement

#000121390024097877 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $2.541M
YoY Change 200.71%
Cost Of Revenue $798.0K
YoY Change 28.92%
Gross Profit $1.743M
YoY Change 671.24%
Gross Profit Margin 68.6%
Selling, General & Admin $1.517M
YoY Change -8.72%
% of Gross Profit 87.03%
Research & Development $543.0K
YoY Change -21.42%
% of Gross Profit 31.15%
Depreciation & Amortization $3.000K
YoY Change -70.0%
% of Gross Profit 0.17%
Operating Expenses $2.060M
YoY Change -12.45%
Operating Profit -$317.0K
YoY Change -85.1%
Interest Expense -$194.0K
YoY Change -220.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$511.0K
YoY Change -41.26%
Income Tax
% Of Pretax Income
Net Earnings -$511.0K
YoY Change -41.06%
Net Earnings / Revenue -20.11%
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$0.09
COMMON SHARES
Basic Shares Outstanding 6.254M shares 6.016M shares
Diluted Shares Outstanding 6.015M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.241M
YoY Change 138.4%
Cash & Equivalents $2.241M
Short-Term Investments $0.00
Other Short-Term Assets $781.0K
YoY Change -27.01%
Inventory $2.372M
Prepaid Expenses
Receivables $1.828M
Other Receivables $0.00
Total Short-Term Assets $7.222M
YoY Change 33.37%
LONG-TERM ASSETS
Property, Plant & Equipment $52.00K
YoY Change -21.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.476M
YoY Change -74.01%
Total Long-Term Assets $1.528M
YoY Change -73.39%
TOTAL ASSETS
Total Short-Term Assets $7.222M
Total Long-Term Assets $1.528M
Total Assets $8.750M
YoY Change -21.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $893.0K
YoY Change -59.22%
Accrued Expenses $2.218M
YoY Change 6.63%
Deferred Revenue $277.0K
YoY Change
Short-Term Debt $927.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.075M
YoY Change -23.47%
LONG-TERM LIABILITIES
Long-Term Debt $150.0K
YoY Change -95.28%
Other Long-Term Liabilities $16.00K
YoY Change -36.0%
Total Long-Term Liabilities $614.0K
YoY Change -82.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.075M
Total Long-Term Liabilities $614.0K
Total Liabilities $5.689M
YoY Change -44.31%
SHAREHOLDERS EQUITY
Retained Earnings -$42.26M
YoY Change 11.93%
Common Stock $1.000K
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.833M
YoY Change
Total Liabilities & Shareholders Equity $8.750M
YoY Change -21.58%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$511.0K
YoY Change -41.06%
Depreciation, Depletion And Amortization $3.000K
YoY Change -70.0%
Cash From Operating Activities -$2.438M
YoY Change 8.36%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.621M
YoY Change -953.16%
NET CHANGE
Cash From Operating Activities -2.438M
Cash From Investing Activities 0.000
Cash From Financing Activities 1.621M
Net Change In Cash -817.0K
YoY Change -51.66%
FREE CASH FLOW
Cash From Operating Activities -$2.438M
Capital Expenditures $0.00
Free Cash Flow -$2.438M
YoY Change 7.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41375
dei Entity Registrant Name
EntityRegistrantName
ACTELIS NETWORKS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2160309
dei Entity Address Address Line1
EntityAddressAddressLine1
4039 Clipper Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Fremont
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94538
dei City Area Code
CityAreaCode
(510)
dei Local Phone Number
LocalPhoneNumber
545-1045
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ASNS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6253715 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2241000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
620000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
197000 usd
CY2024Q3 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
300000 usd
CY2023Q4 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
1565000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
168000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
168000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1828000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
664000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
2372000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2526000 usd
CY2024Q3 asns Allowance For Doubtful Debts Prepaid Expenses
AllowanceForDoubtfulDebtsPrepaidExpenses
181000 usd
CY2023Q4 asns Allowance For Doubtful Debts Prepaid Expenses
AllowanceForDoubtfulDebtsPrepaidExpenses
144000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
481000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
340000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
7222000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5912000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61000 usd
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
592000 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
592000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3330000 usd
CY2024Q3 asns Restricted Bank Deposits Current
RestrictedBankDepositsCurrent
91000 usd
CY2023Q4 asns Restricted Bank Deposits Current
RestrictedBankDepositsCurrent
94000 usd
CY2024Q3 asns Severance Pay Fund Noncurrent
SeverancePayFundNoncurrent
200000 usd
CY2023Q4 asns Severance Pay Fund Noncurrent
SeverancePayFundNoncurrent
238000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
515000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
918000 usd
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
78000 usd
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
78000 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
1528000 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
5311000 usd
CY2024Q3 us-gaap Assets
Assets
8750000 usd
CY2023Q4 us-gaap Assets
Assets
11223000 usd
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
927000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1335000 usd
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
893000 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1769000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
277000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
389000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
760000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
737000 usd
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1033000 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1062000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
450000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
735000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1122000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5075000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6912000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
150000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3154000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
160000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
71000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
62000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
405000 usd
CY2024Q3 asns Accrued Severance Noncurrent
AccruedSeveranceNoncurrent
226000 usd
CY2023Q4 asns Accrued Severance Noncurrent
AccruedSeveranceNoncurrent
270000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23000 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
614000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3923000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
5689000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
10835000 usd
CY2024Q3 asns Warrants To Placement Agent
WarrantsToPlacementAgent
228000 usd
CY2023Q4 asns Warrants To Placement Agent
WarrantsToPlacementAgent
159000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6254664 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6254664 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3007745 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3007745 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
45095000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39916000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42263000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39688000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2833000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
229000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8750000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11223000 usd
us-gaap Revenues
Revenues
6698000 usd
us-gaap Revenues
Revenues
4589000 usd
CY2024Q3 us-gaap Revenues
Revenues
2541000 usd
CY2023Q3 us-gaap Revenues
Revenues
845000 usd
us-gaap Cost Of Revenue
CostOfRevenue
2792000 usd
us-gaap Cost Of Revenue
CostOfRevenue
3043000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
798000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
619000 usd
us-gaap Gross Profit
GrossProfit
3906000 usd
us-gaap Gross Profit
GrossProfit
1546000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
1743000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
226000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1793000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2117000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
543000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
691000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2001000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2332000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
727000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
691000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2398000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2805000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
790000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
971000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
163000 usd
us-gaap Operating Expenses
OperatingExpenses
6029000 usd
us-gaap Operating Expenses
OperatingExpenses
7254000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2060000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2353000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2123000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5708000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-317000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2127000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
590000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
512000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
246000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
161000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
138000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1865000 usd
CY2024Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
52000 usd
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1421000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2575000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4355000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-511000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-867000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.93
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4429738 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4429738 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2254235 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2254235 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6014548 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6014548 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2685626 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2685626 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3265000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
298000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
50000 usd
asns Stock Issued During Period Value Issuance Of Common Stock And Prefunded Warrants Upon Private Placement Net Of Underwriting
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsUponPrivatePlacementNetOfUnderwriting
1356000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
314000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4355000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
838000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
229000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
259000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
316000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
61000 usd
asns Stock Issued During Period Value Warrant Inducement Agreement Net Of Offering Costs
StockIssuedDuringPeriodValueWarrantInducementAgreementNetOfOfferingCosts
1951000 usd
asns Stock Issued During Period V Alue Warrant Inducement Agreement Net Of Offering Costs Note7f
StockIssuedDuringPeriodVAlueWarrantInducementAgreementNetOfOfferingCostsNote7f
2560000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2575000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2833000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1285000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
106000 usd
CY2023Q3 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
314000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-867000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
838000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
936000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
80000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
61000 usd
CY2024Q3 asns Stock Issued During Period Value Warrant Inducement Agreement Net Of Offering Costs
StockIssuedDuringPeriodValueWarrantInducementAgreementNetOfOfferingCosts
1951000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
316000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-511000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2833000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2575000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4355000 usd
us-gaap Depreciation
Depreciation
11000 usd
us-gaap Depreciation
Depreciation
20000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1658000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
223000 usd
us-gaap Inventory Write Down
InventoryWriteDown
39000 usd
us-gaap Inventory Write Down
InventoryWriteDown
132000 usd
us-gaap Interest Expense
InterestExpense
-56000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
58000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
365000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
259000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
298000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
11000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
78000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1164000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2319000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-12000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-25000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-115000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1651000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
140000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-62000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
100000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-875000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
411000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-23000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-262000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-350000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-185000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
35000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-30000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4781000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5194000 usd
asns Proceedsfrom Short Term Deposits
ProceedsfromShortTermDeposits
198000 usd
asns Proceedsfrom Short Term Deposits
ProceedsfromShortTermDeposits
1363000 usd
asns Paymentto Short Term Restricted Bank Deposits
PaymenttoShortTermRestrictedBankDeposits
-75000 usd
asns Payments For Proceeds From Long Term Deposit
PaymentsForProceedsFromLongTermDeposit
2000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
197000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1430000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3500000 usd
asns Proceeds From Issuance Common Stock Net Of Offering Costs
ProceedsFromIssuanceCommonStockNetOfOfferingCosts
316000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
927000 usd
asns Proceeds From Warrant Inducement Agreement
ProceedsFromWarrantInducementAgreement
5248000 usd
asns Proceeds From Underwriting Discounts And Commissions And Other Offering Costs
ProceedsFromUnderwritingDiscountsAndCommissionsAndOtherOfferingCosts
668000 usd
asns Proceeds From Underwriting Discounts And Commissions And Other Offering Costs
ProceedsFromUnderwritingDiscountsAndCommissionsAndOtherOfferingCosts
291000 usd
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-4038000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
193000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
583000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1624000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2586000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-14000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-12000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2974000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1190000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5515000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4279000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2541000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3089000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2241000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
682000 usd
CY2024Q3 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
300000 usd
CY2023Q3 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
2407000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2541000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3089000 usd
us-gaap Interest Paid Net
InterestPaidNet
576000 usd
us-gaap Interest Paid Net
InterestPaidNet
512000 usd
asns Issuance Costs Of Common Stock Prefunded Warrants And Warrants
IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants
104000 usd
asns Reclassification Of Warrants From Liability To Equity Upon Amendment To Private Placement Agreement
ReclassificationOfWarrantsFromLiabilityToEquityUponAmendmentToPrivatePlacementAgreement
314000 usd
asns Issuance Costs Of The Warrant Inducement Agreement
IssuanceCostsOfTheWarrantInducementAgreement
2651000 usd
asns Warrant To Lender
WarrantToLender
61000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2575000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4355000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4781000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5194000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42263000 usd
CY2024Q3 us-gaap Cash
Cash
2541000 usd
CY2024Q3 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
91000 usd
us-gaap Other Income
OtherIncome
163000 usd
us-gaap Use Of Estimates
UseOfEstimates
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates in preparation of financial statements </b></span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of risk</b></span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and trade receivables. Cash and cash equivalents and restricted cash are placed with banks and financial institutions in the United States and Israel.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the condensed consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management provides allowances based upon a specific review of all significant outstanding invoices, analysis of its historical collection experience, and current economic trends. If the historical data used to calculate the allowance for credit losses does not reflect the Company’s future ability to collect outstanding accounts receivable, additional provisions for credit losses may be needed, and the future results of operations could be materially affected.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has customers balances representing 10% or more of Trade receivables as follows:</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 1in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1) </span></p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer A represented 0% and 30% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.</span></p></td></tr> </table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 1in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td> <td style="font-size: 10pt; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font-size: 10pt; text-align: justify">Customer B represented 4.5 % and 11% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.</td></tr> </table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 1in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer C <span style="-sec-ix-hidden: hidden-fact-178">represented0 %</span> and 11% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.</span></p></td></tr> </table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer D represented 38% and 0% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer E represented 21.4% and 0% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not see any credit risk regarding the major trade receivable balance.</span></p>
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1344000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
757000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1028000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1769000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
2372000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2526000 usd
us-gaap Inventory Write Down
InventoryWriteDown
39000 usd
us-gaap Inventory Write Down
InventoryWriteDown
132000 usd
CY2024Q3 us-gaap Inventory Write Down
InventoryWriteDown
14000 usd
CY2023Q3 us-gaap Inventory Write Down
InventoryWriteDown
35000 usd
CY2020Q4 us-gaap Loans Payable
LoansPayable
20000000 ils
CY2020Q4 us-gaap Loans Payable
LoansPayable
6000000 usd
CY2020Q4 us-gaap Financing Receivable Loan In Process
FinancingReceivableLoanInProcess
3000000 usd
CY2021Q1 us-gaap Financing Receivable Loan In Process
FinancingReceivableLoanInProcess
2000000 usd
CY2024Q3 us-gaap Long Term Debt Percentage Bearing Variable Interest Rate
LongTermDebtPercentageBearingVariableInterestRate
0.096 pure
CY2021Q4 asns Received Additional Funding
ReceivedAdditionalFunding
1000000 usd
CY2021Q4 us-gaap Long Term Debt Percentage Bearing Variable Interest Rate
LongTermDebtPercentageBearingVariableInterestRate
0.096 pure
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
1800000 usd
CY2022Q4 us-gaap Carrying Value Of Securities Sold Under Repurchase Agreements And Deposits Received For Securities Loaned
CarryingValueOfSecuritiesSoldUnderRepurchaseAgreementsAndDepositsReceivedForSecuritiesLoaned
2000000 usd
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
2000000 usd
CY2024Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2000000 ils
CY2024Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
550000 usd
CY2024Q2 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
10900000 ils
CY2024Q2 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
10900000 ils
CY2024Q2 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2933000 usd
CY2024Q2 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2933000 usd
CY2024Q1 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.096 pure
CY2024Q1 us-gaap Stock Issued1
StockIssued1
150000 usd
CY2024Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
196000 usd
CY2024Q3 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
1160000 ils
CY2024Q3 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
300000 usd
CY2024Q3 asns Interest Bonus Outstanding
InterestBonusOutstanding
700000 ils
CY2024Q3 asns Interest Bonus Outstanding
InterestBonusOutstanding
200000 usd
CY2024Q1 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.015 pure
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.30 pure
asns Royalties Paid Percentage
RoyaltiesPaidPercentage
1 pure
CY2024Q3 us-gaap Grants Receivable
GrantsReceivable
14300000 usd
CY2024Q3 us-gaap Receivable With Imputed Interest Net Amount
ReceivableWithImputedInterestNetAmount
15830 usd
CY2024Q3 asns Repayment Of Grants
RepaymentOfGrants
10518000 usd
us-gaap Payments For Royalties
PaymentsForRoyalties
1033000 usd
CY2023 us-gaap Payments For Royalties
PaymentsForRoyalties
1062000 usd
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 asns Stock Issued During Period Shares Exercise Of Prefunded Warrants Into Common Stock
StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoCommonStock
754670 shares
CY2023Q2 asns Prefunded Warrants
PrefundedWarrants
754670 shares
CY2023Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.0001
CY2023Q3 asns Stock Issued During Period Shares Exercise Of Prefunded Warrants Into Common Stock
StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoCommonStock
754670 shares
CY2023Q3 asns Stock Issued During Period Shares Exercise Of Prefunded Warrants Into Common Stock
StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoCommonStock
754670 shares
CY2023Q3 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0755
CY2023Q3 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0755
CY2023Q2 asns Payments To Underwriter
PaymentsToUnderwriter
291000 usd
CY2023Q2 asns Warrant Exercise Price Percentage
WarrantExercisePricePercentage
1.25 pure
CY2023Q2 asns Offering Share Price
OfferingSharePrice
4631.3000
CY2023Q4 us-gaap Proceeds From Payments For Long Term Loans For Related Parties
ProceedsFromPaymentsForLongTermLoansForRelatedParties
1500000 usd
CY2023Q4 asns Stock Issued During Period Shares Exercise Of Prefunded Warrants Into Common Stock
StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoCommonStock
970187 shares
CY2023Q4 asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.0001
asns Stock Issued During Period Shares Exercise Of Prefunded Warrants Into Common Stock
StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoCommonStock
970187 shares
asns Exercise Price Of Prefunded Warrant
ExercisePriceOfPrefundedWarrant
0.097
CY2023Q4 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
129000 usd
CY2023Q4 asns Offering Share Price
OfferingSharePrice
1475
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
230000 usd
asns Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Remaining
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisableRemaining
P2Y
CY2024Q2 asns Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
999670 shares
CY2024Q2 asns Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisables
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisables
P2Y
CY2024Q2 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
2
us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
Pursuant to the inducement agreement, the holder agreed to exercise for cash the 2 Years June Warrants to purchase an aggregate of 999,670 shares of the Company’s common stock at an exercise price of $2.00 per share, in consideration of the Company’s agreement to issue new common stock purchase warrants, to purchase up to an aggregate of 1,999,340 shares of common stock (the “July Warrants”), for an exercise price of $1.75 at a 1:1 exchange ratio. As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $250.
CY2024Q2 asns Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Remaining
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisableRemaining
P2Y
CY2024Q3 asns Warrants To Purchase Common Stock
WarrantsToPurchaseCommonStock
1999340 shares
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.75
asns Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisables
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisables
P2Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
87764 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.63
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M9D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
21225 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1159 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.5
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
65380 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y4M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
60799 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y8M12D
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
4602053
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1047589
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
72945 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-511000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-867000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2575000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4355000 usd
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
6014548 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2389296 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3782947 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1998123 shares
CY2023Q3 asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
304250 shares
asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
646791 shares
asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
262712 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
7920 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
6600 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6014548 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6014548 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2685626 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2685626 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4429738 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4429738 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2254235 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2254235 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.93
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Revenues
Revenues
6698000 usd
us-gaap Revenues
Revenues
4589000 usd
CY2024Q3 us-gaap Revenues
Revenues
2541000 usd
CY2023Q3 us-gaap Revenues
Revenues
845000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
460000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
648000 usd
asns Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
607000 usd
CY2023 asns Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
544000 usd
asns Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
584000 usd
CY2023 asns Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
356000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
437000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
460000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
437000 usd
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
usd
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
asns Stock Issue During Period Value Exercise Of Prefunded Warrants Into Common Stock
StockIssueDuringPeriodValueExerciseOfPrefundedWarrantsIntoCommonStock
usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
asns Stock Issued During Period Exercise Of Pre Funded Warrants Into Common Stock Note7b
StockIssuedDuringPeriodExerciseOfPreFundedWarrantsIntoCommonStockNote7b
usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CY2023Q3 asns Stock Issued During Period Exercise Of Pre Funded Warrants Into Common Stock Note7b
StockIssuedDuringPeriodExerciseOfPreFundedWarrantsIntoCommonStockNote7b
usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Interest Expense
InterestExpense
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
asns Paymentto Short Term Restricted Bank Deposits
PaymenttoShortTermRestrictedBankDeposits
usd
asns Payments For Proceeds From Long Term Deposit
PaymentsForProceedsFromLongTermDeposit
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
asns Proceeds From Issuance Common Stock Net Of Offering Costs
ProceedsFromIssuanceCommonStockNetOfOfferingCosts
usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
usd
asns Proceeds From Warrant Inducement Agreement
ProceedsFromWarrantInducementAgreement
usd
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2023Q3 us-gaap Restricted Cash Equivalents Current
RestrictedCashEquivalentsCurrent
usd
CY2024Q3 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
usd
asns Issuance Costs Of Common Stock Prefunded Warrants And Warrants
IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants
usd
asns Reclassification Of Warrants From Liability To Equity Upon Amendment To Private Placement Agreement
ReclassificationOfWarrantsFromLiabilityToEquityUponAmendmentToPrivatePlacementAgreement
usd
asns Issuance Costs Of The Warrant Inducement Agreement
IssuanceCostsOfTheWarrantInducementAgreement
usd
asns Warrant To Lender
WarrantToLender
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q3 asns Pre Funded Warrants To Purchase Common Shares
PreFundedWarrantsToPurchaseCommonShares
shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
shares
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001141284

Files In Submission

Name View Source Status
asns-20240930_cal.xml Edgar Link unprocessable
0001213900-24-097877-index-headers.html Edgar Link pending
0001213900-24-097877-index.html Edgar Link pending
0001213900-24-097877.txt Edgar Link pending
0001213900-24-097877-xbrl.zip Edgar Link pending
asns-20240930.xsd Edgar Link pending
ea0220562-10q_actelis.htm Edgar Link pending
ea022056201ex31-1_actelis.htm Edgar Link pending
ea022056201ex31-2_actelis.htm Edgar Link pending
ea022056201ex32-1_actelis.htm Edgar Link pending
ea022056201ex32-2_actelis.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
asns-20240930_def.xml Edgar Link unprocessable
asns-20240930_lab.xml Edgar Link unprocessable
asns-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0220562-10q_actelis_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending